An androgen receptor N-terminal domain antagonist for treating prostate cancer. - Wikidata - awgldk - TriplyDB

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

http://www.wikidata.org/entity/Q36966859

about

Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting A sting in the tail: the N-terminal domain of the androgen receptor as a drug target Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Persistent androgen receptor addiction in castration-resistant prostate cancer Targeting molecular resistance in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Targeting the androgen receptor in prostate and breast cancer: several new agents in development Targeting the adaptive molecular landscape of castration-resistant prostate cancer Emerging data on androgen receptor splice variants in prostate cancer Characterization of niphatenones that inhibit androgen receptor N-terminal domain Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy High throughput microscopy identifies bisphenol AP, a bisphenol A analog, as a novel AR down-regulator The link between androgen receptor splice variants and castration-resistant prostate cancer.Androgen receptor splice variants and prostate cancer: From bench to bedside.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.Molecular pathways and targets in prostate cancer EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Constitutive activity of the androgen receptor.Research resource: EPSLiM: ensemble predictor for short linear motifs in nuclear hormone receptors.Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy Targets to treat androgen excess in polycystic ovary syndrome.Androgen receptor: structure, role in prostate cancer and drug discovery.A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants NMR WaterLOGSY Reveals Weak Binding of Bisphenol A with Amyloid Fibers of a Conserved 11 Residue Peptide from Androgen Receptor Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen pathway resistance in prostate cancer and therapeutic implications Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy An imaging agent to detect androgen receptor and its active splice variants in prostate cancer ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

P2860

Q26739972-4EBD399F-643D-4782-AE92-47D507BD20FB Q26745907-C0146128-FD0A-4F3D-AAAE-687B804274EF Q26747094-0264B68B-AB90-446D-BFA8-CD8F0CBD8DCB Q26750620-A99E33C7-3B26-49AE-9871-B5B1A7B85AD8 Q26777163-10BC7AE3-F7AB-405F-A1E3-208A264FEEAB Q26795445-DF042AE7-D5D4-4EFA-92BE-593017D4DAEA Q26796704-D96B1EBD-B36A-45F4-9D0B-560B5001DEAD Q26858922-BBAE1851-86A2-42BC-A011-424E48FCEFDD Q27009424-DA4432BF-13C5-4F62-9AD3-12A31FFB66B9 Q27022821-66D40F90-B21E-417D-BB5D-736BED4BF7FC Q28077830-AEEEB161-5323-439A-A55F-E8CBC8B04331 Q28543404-CC9C7B5C-AB23-4F62-8031-405821D25DFE Q28829239-57DC1751-C9BE-4938-9E2A-FEE940544B60 Q28830542-D9875FC6-5AB4-41C3-A14A-D0AA35CF668C Q30618562-87F18C14-33EC-4CFC-9EF9-0770214F0EB1 Q33567024-08DDABC9-5A9B-438E-A8B9-BFE46C23D110 Q33775717-DEBE5AFD-C6D3-4C69-997B-ACF8A9B2B07F Q33821011-6E3F7D09-D3A4-439B-9D7A-9871BF4F92A8 Q33909288-648A2522-EB22-42A7-ADF4-865441113AD0 Q34042831-984F4CC3-EDE1-4DFA-A582-F011C7296469 Q34365632-76A6551D-8907-4312-917E-2673978B0A76 Q34462138-971E35E3-8352-4DF1-A691-598D9ABCD9BA Q34495028-644D3977-88A5-429A-9B0E-D8C2D5529851 Q34775572-3446111D-9A24-40BC-99FB-B2F635A3B7E9 Q35134266-2877EE08-B0C4-4C43-9BCE-E7AFD0D5E52E Q35150756-FC48C14B-2CD8-4D21-BB27-DA038FD9EC29 Q35611451-4637353B-5354-4ADD-A1A6-8A6E8D46917F Q35835501-5A7CEFA1-E5BC-44CF-BCD7-224FB79495FE Q36063723-87FCCD24-845C-4227-8FC7-4931D847E9C0 Q36087132-31AC108D-5A11-457B-B1AE-E121DA91D744 Q36119662-8576FA60-5200-4C07-A9E0-5D7C9F737337 Q36312095-84C6E9DD-68EB-48ED-B712-682CBB941804 Q36398998-9A4BC64B-52E4-454C-8BA7-6286C49372BA Q36416370-E71418B7-8EC3-41AC-B048-0E42C50A8CFB Q36470627-983AC57B-55CB-4AD9-BAAF-4D7F7FF2D866 Q36849142-DED5FDC9-FE7C-4C17-91F0-C6F2FA703FA1 Q36963697-6FCA87BC-AFBC-45FB-89D3-3779844682C6 Q36978557-D547261A-5186-431D-BDD6-AAD1AC499BF0 Q37165574-837418D6-F5B3-4A36-AACF-03A596E014E2 Q37270422-B557A1EF-DF04-4DC0-9E63-3A6F995F36F7

P2860

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

http://www.wikidata.org/entity/Q36966859

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

@en

type

label

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

@en

prefLabel

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

@en

P1433

Q36966859-50470829-4C8A-4E54-9A7E-5572851C96AD

P1476

Q36966859-6D131464-284A-434A-81EE-F7B6E4B94B17

P2093

Q36966859-14CBEF5D-5C8F-4730-8122-1F6EF6D82FD3

Q36966859-2229CA62-B56A-4F04-BA59-AE124BF6350A

Q36966859-26C7FA9E-A3B5-4D26-96C6-7ED8BB9751A1

Q36966859-357BBF32-7713-49EA-AF43-F72600B6C683

Q36966859-4067EEF8-B9A2-4C64-9814-E6532772A5BF

Q36966859-64A44802-BAA5-4C1F-9895-D7BF199D80D5

Q36966859-6E191300-9791-45FD-AA55-C58CDEC79053

Q36966859-7EBE8E52-CED1-4EC9-ADCE-B344D588818B

Q36966859-987FA115-78A2-4ED2-AD82-1C294D4F7588

Q36966859-A5F721B6-4C2D-40AD-B1AC-60CF7B7FA4D8

P2860

Q36966859-00CDCF19-B836-445A-82E7-8E0E12469B1A

Q36966859-18F0D287-DCE5-4FE4-9C61-0E1E510B2C70

Q36966859-1981B038-B030-41B0-88F6-75AA99E423D0

Q36966859-1A14EB01-CE4D-45EA-BAA9-F36F366B8112

Q36966859-1CC340A1-E9CA-4662-B6D2-44178D0A3B0B

Q36966859-1DEAB4A5-5A08-4BD7-A408-FFDFFFEA9537

Q36966859-23CFBA7C-8CE7-4994-A59E-55EA35F826EB

Q36966859-266FDAF0-EBA0-49F7-902D-21237317B9E3

Q36966859-31804D1E-0C79-4DB3-BCC4-1A8D463D4976

Q36966859-39BE9496-B63B-490D-BF3F-43AF5CB0E826

P304

Q36966859-EB6E1B2C-5C83-4759-B9D3-BCA3E753D543

P31

Q36966859-65901F90-3000-4AED-8128-4AB16432D568

P356

Q36966859-021EA7FD-109D-4CAB-A5C7-007BA7D1B529

P407

Q36966859-78B2C1CD-0949-4FE3-9FA5-191A18496A36

P433

Q36966859-23DD3BE5-13DA-4EEE-8391-81BCAA13384F

P478

Q36966859-C248F5CE-B88A-45C7-9E19-8272FB9A522A

P50

Q36966859-E1537271-02AB-4EA5-9AF9-3B5893A9FC22

Q36966859-F887BA44-B363-4A97-9733-8332C6871AA6

P577

Q36966859-B4E68A9A-C6F2-40E4-9FAF-35CB24D703AF

P698

Q36966859-0BCA5CC2-F8BB-4C3C-919A-48140A282465

P932

Q36966859-5864F97D-5984-4459-8890-F114AEF47071

P356

P1433

Journal of Clinical Investigation

P1476

An androgen receptor N-terminal domain antagonist for treating prostate cancer

@en

P2093

Amy H Tien

http://www.w3.org/2001/XMLSchema#string

Carmen A Banuelos

http://www.w3.org/2001/XMLSchema#string

Iain J McEwan

http://www.w3.org/2001/XMLSchema#string

Iran Tavakoli

http://www.w3.org/2001/XMLSchema#string

Jae-Kyung Myung

http://www.w3.org/2001/XMLSchema#string

Javier Garcia Fernandez

http://www.w3.org/2001/XMLSchema#string

Jun Wang

http://www.w3.org/2001/XMLSchema#string

Kate Watt

http://www.w3.org/2001/XMLSchema#string

Nasrin R Mawji

http://www.w3.org/2001/XMLSchema#string

Raymond J Andersen

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF

CREB-binding protein in androgen receptor-mediated signaling

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

Molecular determinants of resistance to antiandrogen therapy

P304

2948-2960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI66398

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23722902

http://www.w3.org/2001/XMLSchema#string

P932

3696543

http://www.w3.org/2001/XMLSchema#string